Anavex life sciences announces completion of anavex(®)2-73 (blarcamesine) excellence phase 2/3 rett syndrome clinical trial

New york, june 06, 2023 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced the completion of dosing of all participants of the placebo-controlled excellence phase 2/3 study anavex®2-73-rs-003 in pediatric patients with rett syndrome. the company expects to announce topline results from this study in the second half of this year.
AVXL Ratings Summary
AVXL Quant Ranking